Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders.
We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy.
Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders.
A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety.
Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.
Company Details
- Employees
- 9
- Address
- Zurich, Ch
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.somagenetix.com
- HQ
- Zurich
Somagenetix Questions
Somagenetix's website is http://www.somagenetix.com
Somagenetix's LinkedIn profile is https://ch.linkedin.com/company/somagenetix
Somagenetix has
9 employees.
View email and phone details for 9
employees at Somagenetix.
Somagenetix's industry is
Pharmaceutical Manufacturing
Somagenetix's top competitors are
Enara Bio,
Adva Biotechnology,
Aditum Bio,
City Therapeutics,
Lymphatica Medtech,
Verismo Therapeutics,
Opencell Technologies, Inc.,
Develco Pharma Schweiz Ag,
Xfarm Technologies,
Aviadobio.
Somagenetix's categories are Pharmaceutical Manufacturing
